0.2249
0.0338 (17.69%)
0.0338 (17.69%)
Upgrade to Real-Time
Afterhours (Closed)
Volume | 12,142,788 |
|
|||||
News | - | ||||||
Day High | 0.28 | Low High |
|||||
Day Low | 0.2011 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Athenex Inc | ATNX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.2028 | 0.2011 | 0.28 | 0.221 | 0.1911 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
15,829 | 12,142,788 | $ 0.2413167 | $ 2,930,258 | - | 0.1184 - 1.20 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:59:41 | formt | 100 | $ 0.2249 | USD |
Athenex Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 35.40M | 157.41M | 121.85M | $ 120.18M | $ -89.55M | -1.92 | -0.10 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | - | 742.63k | 5.30% |
Athenex News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ATNX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.19 | 0.28 | 0.18 | 0.1887681 | 1,164,070 | 0.0349 | 18.37% |
1 Month | 0.1791 | 0.28 | 0.1704 | 0.1838153 | 1,306,311 | 0.0458 | 25.57% |
3 Months | 0.205 | 0.30 | 0.1184 | 0.1643791 | 4,223,298 | 0.0199 | 9.71% |
6 Months | 0.55 | 1.19 | 0.1184 | 0.2893849 | 2,994,477 | -0.3251 | -59.11% |
1 Year | 1.00 | 1.20 | 0.1184 | 0.3722138 | 1,990,004 | -0.7751 | -77.51% |
3 Years | 13.35 | 15.67 | 0.1184 | 3.91 | 1,783,686 | -13.13 | -98.32% |
5 Years | 14.31 | 22.00 | 0.1184 | 5.61 | 1,278,537 | -14.09 | -98.43% |
Athenex Description
Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Its current clinical pipeline is derived from Orascovery, based on a P-glycoprotein (P-gp) pump inhibitor, Src Kinase inhibition, T-cell receptor-engineered T-cells, and arginine deprivation therapy technology platforms. It is primarily engaged in conducting research and development activities through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting preclinical and clinical testing, recruiting personnel, identifying and evaluating additional drug candidates for potential in-licensing or acquisition, and raising capital to support development and commercialization activities. |